Anxiety and depression often occur together. When they do, symptoms can overlap and interact, affecting everything from your energy and motivation to sleep, concentration, relationships and daily life.

If you are experiencing both, you may wonder whether treatment has to address them separately or whether one treatment plan can account for your full symptom picture.

TMS therapy may be considered for certain patients experiencing depression with co-occurring anxiety symptoms.

At Neurotherapeutix, treatment planning looks beyond diagnosis alone. We use functional brain imaging and computational analysis to understand connectivity patterns in your individual brain and determine how to personalize treatment to your symptoms.

Learn more about TMS therapy for depression and our approach to TMS therapy for anxiety.

Quick answer: Can TMS therapy treat co-occurring anxiety and depression?

TMS therapy may help some people who experience depression along with anxiety symptoms.

Rather than assuming the two conditions should be treated identically, your clinical team can evaluate your full symptom profile and determine which brain networks and treatment targets are most relevant.

At Neurotherapeutix, fMRI-guided TMS treatment allows that planning to reflect your individual functional brain organization rather than relying only on a standard treatment location.

Treatment response varies, and improvement in depression does not guarantee the same degree or timing of improvement in anxiety.

How common are co-occurring anxiety and depression?

Depression and anxiety are distinct conditions, but they frequently occur together.

Someone experiencing depression may also have persistent worry, tension, restlessness or fear. A person primarily seeking help for anxiety may also experience low mood, loss of interest, fatigue or feelings of hopelessness.

The National Institute of Mental Health notes that anxiety disorders can occur alongside depression and other mental health conditions. This overlap is one reason a comprehensive evaluation matters.

Having both conditions does not necessarily mean they have the same cause or involve exactly the same areas of the brain. Mental health conditions are complex, and symptom patterns can differ substantially from one person to another.

For treatment planning, the more important question is not simply: Which diagnoses do you have? It is: What does your individual symptom presentation and brain function tell us about how treatment should be approached?

How TMS therapy addresses co-occurring symptoms

Transcranial magnetic stimulation (TMS) uses magnetic pulses to influence activity within targeted areas of the brain and connected networks.

TMS is an established treatment for major depressive disorder, including for certain patients whose symptoms have not adequately improved with other treatments.

Research has also examined how TMS may affect anxiety symptoms, including anxiety occurring alongside depression.

That does not mean depression and anxiety are interchangeable or that there is one universal brain target responsible for both.

Mood regulation, emotional processing, attention, and responses to stress involve interconnected brain networks. The way those networks function can vary among patients, even when they share the same diagnoses.

At Neurotherapeutix, fMRI-guided TMS therapy is designed around that individual variability.

Instead of beginning with the assumption that every person with depression, anxiety, or both should receive stimulation in essentially the same location, we first examine how functional networks throughout your brain are communicating.

That information can then help inform an individualized treatment plan based on your brain activity, symptoms and clinical history.

Why computational brain mapping matters when symptoms overlap

Two people can both be diagnosed with anxiety and depression and still experience those conditions very differently.

One person may struggle primarily with low mood, loss of motivation and persistent worry. Another may experience physical tension, difficulty sleeping, racing thoughts and an inability to enjoy activities they once valued.

Their diagnoses may look similar on paper, but their functional brain connectivity may not.

That is where computational brain mapping becomes particularly useful.

At Neurotherapeutix, your evaluation begins with resting-state functional magnetic resonance imaging (rsfMRI). Unlike a standard structural MRI, which primarily shows brain anatomy, rsfMRI measures patterns of activity and communication among functional brain networks while you are at rest.

Our patented computational technology analyzes those connectivity patterns to identify individualized areas of interest based on your functional brain organization.

The fMRI analysis identifies individualized treatment targets within the patient’s own brain anatomy. These selected target regions are then uploaded into the neuronavigation system, allowing the clinical team to consistently position the TMS coil over the intended anatomical tissue with millimeter-level precision throughout treatment..

For someone experiencing overlapping symptoms, this whole-brain approach provides information that diagnosis alone cannot: a view of how your functional brain networks are organized.

It does not guarantee that TMS therapy will improve both anxiety and depression. Instead, it allows treatment planning to be informed by individual brain function rather than relying only on standardized targeting.

What treatment looks like for co-occurring anxiety and depression

Your treatment begins with a clinical evaluation rather than a predetermined protocol.

The Neurotherapeutix team reviews your symptoms, diagnoses, medical and psychiatric history, medications, previous treatments and response to care.

When clinically appropriate, we use computational brain mapping to evaluate your individual functional connectivity and identify potential treatment targets.

Your fMRI findings are then considered alongside your clinical presentation to develop an individualized treatment plan.

During fMRI-guided TMS therapy, magnetic pulses are delivered non-invasively while you remain awake and seated. TMS does not require surgery or anesthesia, and patients generally return to their normal activities after a session.

Your clinical response is monitored throughout treatment. When you have both depression and anxiety symptoms, those symptoms may not change at the same time or to the same degree. Tracking them individually gives your treatment team a clearer picture of how you are responding.

fMRI-guided TMS therapy may also be provided alongside other forms of care, such as psychiatric treatment, medication management or psychotherapy, when clinically appropriate.

Am I a candidate if I have both conditions?

Having both anxiety and depression does not automatically rule you out as a candidate for TMS therapy.

Candidacy depends on your individual clinical circumstances, including your diagnosis, symptoms, treatment history, medical and neurological history, current medications and other safety considerations.

At Neurotherapeutix, we also consider what your functional brain imaging shows before determining how fMRI-guided treatment may fit into your care.

Learn more about TMS therapy candidacy and what our team considers during an evaluation.

Frequently asked questions

For more information about treatment, eligibility, side effects and what to expect, explore our frequently asked questions.

Can one TMS treatment plan address both anxiety and depression?

Potentially. When depression and anxiety symptoms occur together, your clinical team can consider your complete symptom presentation when developing a TMS treatment plan.

This does not necessarily mean one stimulation target independently “treats” two diagnoses.

At Neurotherapeutix, functional brain imaging and computational analysis help determine which individualized treatment targets may be relevant based on your brain connectivity and clinical needs.

Is TMS therapy effective for anxiety that occurs alongside depression?

Research suggests TMS may improve anxiety symptoms in some patients with depression and co-occurring anxiety. However, response varies among individuals, and the evidence and regulatory status of TMS differ by condition and treatment protocol.

Your clinical evaluation can help determine whether fMRI-guided TMS therapy may be appropriate based on your diagnoses, symptoms and treatment history.

Does treating one condition improve the other?

It may, but improvement in one condition does not guarantee improvement in the other.

Anxiety and depression can interact, so changes in one group of symptoms may affect your overall functioning and well-being. However, they remain distinct clinical conditions, and each person responds differently to treatment.

Your treatment team can monitor anxiety and depressive symptoms separately throughout care to understand how each is responding.

How does Neurotherapeutix personalize treatment for comorbid symptoms?

We begin by looking beyond diagnosis alone.

Resting-state fMRI measures communication across functional networks throughout your brain. Our patented computational brain mapping technology analyzes those patterns and helps identify individualized areas of interest that may inform treatment targeting.

Your imaging findings are considered alongside your symptoms, clinical history and previous treatment response to create an individualized plan. Neuronavigation is then used during TMS therapy to consistently locate the selected treatment target.

A treatment plan built around your full symptom picture

When anxiety and depression occur together, you should not have to fit your experience into a one-size-fits-all treatment plan.

Neurotherapeutix is the only clinic in the United States offering our patented fMRI-guided TMS therapy. From our Upper East Side clinic in Manhattan, we combine whole-brain functional imaging, computational analysis and precisely targeted stimulation to personalize treatment based on your individual brain.

If you are living with depression, anxiety or both, our team can help you understand whether fMRI-guided TMS therapy may be appropriate for your needs.

Request an appointment to learn more and get started.

Trying one antidepressant after another without getting the relief you hoped for can leave you wondering why your depression has been so difficult to treat and what options are left.

When depression symptoms persist despite adequate antidepressant treatment, you may be experiencing treatment-resistant depression. This does not mean depression cannot be treated. It may mean it is time to consider a treatment that works differently.

Transcranial magnetic stimulation (TMS) therapy is a non-invasive brain stimulation treatment that may be considered when antidepressant medication has not provided sufficient relief. Rather than introducing another medication, TMS uses magnetic pulses to influence activity within brain networks involved in depression.

Quick answer: Can TMS therapy help when antidepressants haven’t worked?

Yes. TMS therapy may help some people with depression who have not experienced adequate improvement with antidepressant medication. In fact, inadequate response to antidepressant treatment is one of the circumstances in which TMS is commonly considered.

TMS works differently from medication by using magnetic stimulation to influence targeted brain activity. However, response varies, and previous medication failure does not guarantee that TMS will be effective.

A clinical evaluation can help determine whether TMS therapy may be appropriate for you.

Why antidepressants don’t work for everyone

Antidepressants are an important and effective treatment for many people with depression, but no single medication works for everyone.

The landmark STAR*D study, funded by the National Institute of Mental Health, followed patients through multiple treatment steps when their depression did not remit with an initial antidepressant. The research demonstrated an important clinical reality: some patients achieve remission with the first medication they try, while others require additional treatment strategies, and the likelihood of remission generally decreases with each successive treatment step.

The findings helped establish the need for multiple evidence-based approaches to depression when an initial medication is not enough.

There are many possible reasons an antidepressant may not provide sufficient relief.

Depression is a complex condition involving biological, psychological and environmental factors, and people can differ in their symptoms, treatment history and response to medication.

A lack of response does not necessarily tell you why a particular antidepressant did not work. It does, however, provide useful clinical information when your treatment team considers what to try next.

If adequate medication trials have not produced sufficient improvement, your clinician may discuss changing medication, psychotherapy, combination treatment, brain stimulation or other approaches based on your individual circumstances.

How TMS therapy works when medication hasn’t

Antidepressants and TMS approach depression differently.

Medication is taken systemically and affects biological processes associated with depression throughout the body and brain. TMS does not require medication to reach the brain through the bloodstream. Instead, it uses a magnetic field generated outside the head to induce electrical activity in targeted brain tissue.

For depression, conventional TMS therapy commonly targets an area of the prefrontal cortex involved in mood-related brain networks.

Repeated stimulation can influence activity within those networks over the course of treatment. Because this mechanism is different from antidepressant medication, a previous lack of response to medication does not necessarily mean you will not respond to TMS therapy.

That distinction is one reason TMS therapy may be considered for people whose symptoms have persisted despite antidepressant treatment.

At Neurotherapeutix, fMRI-guided TMS therapy adds individualized functional brain imaging and computational analysis to this process.

If you are specifically exploring treatment for persistent depression, you can also learn more about TMS therapy for depression and how Neurotherapeutix approaches treatment planning.

Why fMRI-guided TMS therapy offers a more individualized approach

Standard TMS therapy typically identifies a stimulation target using standardized anatomical measurements or scalp-based landmarks. This allows clinicians to target a general brain region associated with the condition being treated.

Neurotherapeutix takes a different approach.

Before treatment begins, resting-state functional magnetic resonance imaging (rsfMRI) measures patterns of activity and communication across functional networks throughout your brain.

Our patented computational brain mapping technology then analyzes those connectivity patterns to identify individualized areas of interest based on your functional brain organization.

The fMRI analysis identifies individualized areas of brain tissue with functional patterns relevant to the patient’s symptoms. These targets are uploaded into the neuronavigation system, allowing the treatment team to consistently and precisely position the TMS coil over the selected anatomical region with millimeter-level accuracy throughout therapy.

This means treatment planning is informed by how your individual brain is functioning rather than relying only on a standard treatment location.

For someone who has already tried several treatments without sufficient improvement, this may provide additional information not included in previous treatment planning.

However, personalized targeting does not guarantee a response to TMS therapy. The value of the approach is that it gives your clinical team an individualized view of functional brain connectivity that can help inform where treatment is delivered.

What the research says about TMS therapy after antidepressants fail

TMS has been studied extensively in depression, including among patients whose symptoms have not adequately improved with antidepressant treatment.

The FDA first cleared repetitive TMS for the treatment of major depressive disorder in adults who had not achieved satisfactory improvement from a prior antidepressant medication in the current depressive episode. Since then, TMS technologies and indications have continued to evolve.

Clinical research has found that some patients with treatment-resistant depression experience a meaningful reduction in symptoms with TMS, and some achieve remission.

Response rates vary among studies because patient populations, treatment protocols, definitions of response and other factors differ.

The key point is not that TMS will work because antidepressants did not. It is that antidepressant nonresponse does not rule out the possibility of responding to a treatment that works through a different mechanism.

Is fMRI-guided TMS therapy right for you after failed medication?

If you have tried one or more antidepressants without sufficient improvement, fMRI-guided TMS therapy may be worth discussing with a qualified clinician.

Your evaluation should consider more than the number of medications you have tried. Your treatment team may review:

• Your diagnosis and current symptoms
• How long you have experienced symptoms
• Which antidepressants and other medications you have tried
• Whether those medications were taken at adequate doses and for adequate lengths of time
• Your response to psychotherapy or other treatments
• Previous TMS or other brain stimulation treatment
• Your medical and neurological history
• Current medications and potential safety considerations

You can learn more about TMS therapy candidacy and the factors Neurotherapeutix considers before recommending treatment.

Having treatment-resistant depression does not automatically make someone a candidate for TMS, and TMS is not appropriate for everyone. An individualized clinical evaluation is the best way to determine whether it may fit into your treatment plan.

Frequently asked questions

Have additional questions about treatment, side effects or what to expect? Visit our frequently asked questions for more information about fMRI-guided TMS therapy at Neurotherapeutix.

Is TMS therapy effective if antidepressants didn’t work?

It can be.

TMS is an established treatment option for some patients with depression who have not experienced adequate improvement with antidepressant medication.

Clinical studies have shown that some people with treatment-resistant depression experience symptom improvement or remission following TMS.

However, treatment response varies, and previous antidepressant failure does not predict with certainty whether an individual patient will respond to TMS.

How is TMS therapy different from taking another medication?

The treatments work through different mechanisms.

Antidepressant medications affect biological processes associated with depression through pharmacological action. TMS uses magnetic pulses delivered from outside the head to influence activity in targeted areas of the brain and connected networks.

TMS is also non-invasive and does not require surgery or anesthesia.

Do I need to stop my current medication to try fMRI-guided TMS therapy?

Not necessarily.

Many patients receive fMRI-guided TMS therapy while continuing antidepressant or other psychiatric medication. Whether you should continue, change or discontinue a medication depends on your individual treatment plan.

Your clinician should review all medications before TMS begins because certain medications or recent medication changes may affect treatment planning or seizure risk.

Do not stop an antidepressant or change your dose on your own in preparation for TMS.

Abruptly discontinuing some antidepressants can cause withdrawal symptoms or other problems.

How soon can I start TMS therapy after stopping antidepressants?

There is no universal waiting period because you do not necessarily need to stop antidepressants before beginning TMS.

If you and the clinician managing your medication decide to reduce or discontinue a medication, the appropriate timeline depends on the specific medication, dose, how long you have been taking it, and your individual medical circumstances.

Your Neurotherapeutix team will review your current and recent medications during your evaluation and coordinate treatment planning accordingly.

Explore a different approach to persistent depression

If antidepressants have not given you the relief you hoped for, another medication is not necessarily your only next step.

Neurotherapeutix is the only clinic in the United States offering its patented fMRI-guided TMS therapy. Our approach combines whole-brain functional imaging, computational brain mapping, individualized targeting and neuronavigation to personalize treatment based on your individual brain function.

Our team can review your treatment history, discuss whether fMRI-guided TMS therapy may be appropriate and help you understand what an individualized treatment plan could look like.

Request an appointment today to learn more and get started.

When you’re considering transcranial magnetic stimulation (TMS) therapy for depression, one of the first practical questions is often how much time treatment will require.

Knowing how many sessions to expect can help you plan around work, family, travel and the financial commitment involved in care.

A standard TMS treatment course often takes place over several weeks, but there is no single session count that applies to every patient. The protocol being used, your clinical needs, and your response to treatment can all influence the course your clinician recommends.

At Neurotherapeutix, fMRI-guided TMS therapy adds functional brain imaging and individualized targeting to treatment planning.

Depending on your imaging findings and clinical needs, treatment may follow a traditional schedule or, when clinically appropriate, an accelerated protocol with multiple sessions delivered in a single day.

Quick answer: Typical TMS therapy session counts for depression

A standard course of TMS therapy for depression commonly involves treatment five days per week for approximately four to six weeks.

Depending on the protocol, this may mean roughly 20 to 30 or more treatment sessions, and some patients may benefit from additional sessions.

The exact number varies. Your clinician may consider the treatment protocol, your symptoms, previous treatment history, response to TMS and other individual factors when determining your treatment course.

Standard TMS therapy treatment timeline

Traditional TMS treatment for depression is generally delivered on an outpatient basis over several weeks.

Clinical TMS Society consensus recommendations have historically described an acute course of approximately 20 to 30 sessions over four to six weeks, although treatment may be extended when clinically appropriate.

For many patients, this means coming to the clinic five days per week. The goal is to deliver repeated stimulation over time while monitoring symptoms and clinical response.

There is no universal week when you should expect to notice improvement. Some people may begin noticing changes earlier in the treatment course, while others respond later or require additional treatment. Not experiencing an immediate change does not necessarily mean TMS will not be effective for you.

Your clinical team should monitor your progress throughout treatment rather than assuming that every patient will follow the same response timeline.

What affects how many sessions you’ll need?

There is no formula that can determine exactly how many TMS sessions you will need before treatment begins.

Your treatment plan may take several factors into account, including:

• Your diagnosis and symptoms: Your clinical presentation helps your treatment team determine which treatment approach may be appropriate.
• Your previous treatment history: Your response to antidepressants, psychotherapy, previous TMS therapy and other treatments provides important context for treatment planning.
• The TMS protocol: Different protocols use different stimulation patterns, treatment durations and schedules.
• Your response during treatment: Your clinical team can monitor changes in your symptoms and determine whether the treatment course should continue or be adjusted.
• Whether an accelerated protocol is appropriate: Some protocols deliver multiple sessions within the same day, potentially shortening the overall number of calendar days spent in treatment.

If depression has continued despite previous treatment, learning more about TMS therapy for depression can help you understand how brain stimulation may fit into a broader treatment plan.

Importantly, needing additional sessions does not mean you have failed treatment. Response to TMS varies among individuals, and your treatment course should be guided by your clinical needs rather than by reaching a predetermined number as quickly as possible.

Why fMRI-guided TMS therapy can change the treatment schedule

Standard TMS therapy typically identifies treatment targets using standardized anatomical measurements or scalp-based landmarks. Neurotherapeutix takes a different approach.

Before fMRI-guided TMS therapy begins, resting-state functional magnetic resonance imaging (rsfMRI) is used to measure patterns of activity throughout your brain while you are at rest.

The Neurotherapeutix team then uses patented computational brain mapping technology to analyze functional connectivity, or how activity in different areas of your brain is related over time.

These findings help identify individualized treatment targets based on your functional brain organization. Neuronavigation then helps the treatment team precisely locate those targets during treatment.

This is a key distinction between personalized TMS vs. standard TMS: the treatment target is informed by your individual functional brain connectivity rather than relying only on a standardized anatomical location.

However, personalized targeting does not automatically mean you will need fewer TMS sessions.

At Neurotherapeutix, imaging findings can help inform your individualized treatment plan, including the treatment target and protocol. When clinically appropriate, accelerated protocols may also be available.

An accelerated schedule generally means receiving multiple treatment sessions in one day. This can reduce the number of days required to complete treatment without necessarily reducing the total number of sessions delivered.

Your treatment team can determine which approach is appropriate based on your imaging, clinical evaluation and individual needs.

What a single fMRI-guided TMS therapy session involves

During a TMS therapy session at Neurotherapeutix, you remain awake and seated in a treatment chair. No surgery or anesthesia is required.

A magnetic coil is positioned against your scalp at the identified treatment location. The device then delivers repeated magnetic pulses to stimulate the targeted area of the brain.

During stimulation, you may hear clicking from the device and feel tapping, pressure or other sensations on your scalp. Some patients experience temporary scalp discomfort or headache, particularly early in treatment.

Session length varies according to the specific TMS protocol being used. Some standard protocols may take approximately 20 to 40 minutes, while other protocols can be shorter.

TMS is generally performed on an outpatient basis and does not require a post-treatment recovery period. Most patients can return to their usual daily activities after the session.

Frequently asked questions

Still have questions about treatment, eligibility, side effects or what to expect at Neurotherapeutix? Visit our frequently asked questions for additional information about fMRI-guided TMS therapy.

How many TMS sessions are typically needed for depression?

A standard acute course commonly involves approximately 20 to 30 or more sessions delivered over four to six weeks, often five days per week. The exact number depends on the protocol, your clinical needs and your response to treatment.

Some patients may benefit from treatment beyond the initial course, so your clinician should evaluate your progress rather than relying on a predetermined session count alone.

How long does each TMS session last?

Session length depends on the protocol being used. Some TMS sessions may take approximately 20 to 40 minutes, while other protocols can be considerably shorter.

Because TMS does not require anesthesia, patients generally do not need a recovery period afterward.

Can treatment take fewer sessions with computational brain mapping?

Not necessarily. Computational brain mapping helps Neurotherapeutix individualize where stimulation is delivered, but brain mapping alone does not establish that you will need fewer total treatment sessions.

Your imaging findings, clinical needs and response to treatment can help inform your treatment plan. When clinically appropriate, an accelerated protocol may allow multiple sessions to be delivered in one day, shortening the treatment timeline in calendar days without necessarily reducing the total number of sessions.

What happens if I don’t improve after the standard course?

Not responding within a standard treatment course does not automatically mean there are no additional options.

Your clinician can review your symptoms, treatment response and previous protocol to determine whether continued treatment, a different approach or another intervention may be appropriate.

For someone who previously received standard TMS, individualized functional imaging and targeting may also provide additional information to consider when evaluating next steps. However, fMRI-guided targeting cannot guarantee that someone who did not respond to standard TMS will respond to another course.

At Neurotherapeutix, patients are typically imaged again after completing an fMRI-guided TMS treatment course. The follow-up scan helps objectively assess treatment-related changes and guide next steps in care.

If the clinical response is incomplete, the clinical team may recommend additional treatment sessions or an updated, individualized treatment protocol that targets additional brain regions, based on the follow-up imaging findings and the patient’s symptoms.

Explore a TMS treatment plan built around your brain

There is no single TMS treatment schedule that is right for every person with depression. Understanding your symptoms, treatment history, and individual brain function can help your clinical team determine an appropriate approach.

If you are considering treatment, learn more about TMS therapy candidacy and whether brain stimulation may be appropriate for your needs.

Neurotherapeutix is the only clinic in the United States offering its patented fMRI-guided TMS therapy, combining whole-brain functional imaging, computational brain mapping, individualized targeting and neuronavigation to personalize treatment.

If you’re ready to learn what your treatment plan could look like, request an appointment with our team at our Upper East Side Manhattan clinic.

When depression symptoms continue despite treatment, it can be frustrating and difficult to understand what comes next. You may have taken one medication, waited to see whether it would help, tried another and still found yourself living with symptoms that affect your mood, energy, relationships or ability to function.

Treatment-resistant depression (TRD) is the term commonly used when depression has not adequately improved after multiple appropriate antidepressant treatments. It does not mean your depression is untreatable. It means your current approach has not provided the improvement you need, and it may be time to consider other treatment strategies.

For some people, those options may include fMRI-guided TMS therapy, which takes a different approach by using functional brain imaging and individualized targeting to inform where transcranial magnetic stimulation (TMS) is delivered.

Quick answer: What is treatment-resistant depression?

Treatment-resistant depression generally describes major depressive disorder that has not adequately improved after at least two antidepressant treatments taken at an appropriate dose, for an adequate amount of time and with appropriate adherence.

There is not one universally accepted definition of TRD, but the two-treatment threshold is commonly used in clinical and research settings.

Most importantly, treatment resistance does not mean treatment is no longer possible. Other therapeutic approaches may still help.

How is treatment-resistant depression defined?

There is no single definition of treatment-resistant depression used by every clinician or researcher. However, the U.S. Food and Drug Administration (FDA) and European Medicines Agency have used a commonly accepted definition: an inadequate response to at least two antidepressants despite adequate treatment trials and adherence.

An “adequate” medication trial generally means that the medication was taken at a therapeutic dose for enough time to reasonably evaluate its effect. The exact dose and duration depend on the medication, the individual and the clinical situation.

This distinction matters. Stopping a medication early because of side effects, taking a dose that was not therapeutically adequate or missing doses may make it difficult to determine whether the medication itself was ineffective.

Your clinician may also look beyond the number of medications you have tried. Your diagnosis, symptom severity, duration of illness, previous response to treatment, co-occurring conditions, medication tolerance and other factors can all influence how your depression is evaluated.

The National Institute of Mental Health’s landmark STAR*D study also demonstrated why reassessment becomes increasingly important when initial treatments do not produce remission.

Participants could progress through several treatment levels when earlier approaches were unsuccessful, and the likelihood of remission generally declined as additional treatment steps were required.

If your symptoms have persisted despite antidepressant treatment, learning more about TMS therapy for depression can help you understand one of the non-medication options that may be considered.

Signs you may have treatment-resistant depression

Treatment-resistant depression is not defined by having “worse” depression than someone else. Instead, the pattern of your response to treatment is an important part of the picture.

You may want to speak with your clinician about treatment-resistant depression if:

• You have completed two or more appropriate antidepressant trials without adequate improvement.
• Your symptoms improve somewhat with medication but continue to significantly affect your daily life.
• A medication initially seems helpful, but meaningful symptoms persist or return.
• Side effects make it difficult to continue otherwise appropriate medication treatment.
• You continue to experience symptoms such as persistent low mood, loss of interest or pleasure, changes in sleep, difficulty concentrating, fatigue or changes in appetite despite ongoing treatment.

These patterns do not automatically mean you have TRD. Other factors can affect treatment response, and your clinician may need to reconsider the diagnosis, look for co-occurring psychiatric or medical conditions, review medication adherence or explore other reasons your symptoms have persisted.

It can be helpful to keep a record of the antidepressants you have taken, including the dose, how long you took each medication, side effects and whether your symptoms changed. That information can give your clinician a clearer view of your treatment history.

Why some depression doesn’t respond to medication

Depression is complex, and there is no single biological explanation for why one person responds well to an antidepressant while another does not.

Genetics, neurotransmitter systems, functional brain networks, co-occurring medical or psychiatric conditions, environmental factors and differences in individual biology may all influence how depression develops and responds to treatment.

Many antidepressants affect neurotransmitter systems such as serotonin and norepinephrine. These medications can be effective for many people, but medication is not the only way to influence the systems involved in depression.

Research has also identified changes in patterns of activity and communication among brain networks involved in mood, cognition and emotional regulation.

Scientists continue to study how those patterns differ among people with depression and whether differences in functional connectivity may help explain variations in treatment response.

This broader understanding of depression is one reason brain-stimulation treatments such as transcranial magnetic stimulation have become important options for some people whose symptoms persist despite medication.

TMS does not work in the same way as an antidepressant. Instead, it uses magnetic pulses to stimulate targeted areas of the brain involved in functional networks associated with depression.

How Neurotherapeutix approaches treatment-resistant depression

At Neurotherapeutix, treatment planning begins by looking beyond diagnosis alone.

Standard TMS therapy typically identifies treatment locations using standardized anatomical measurements or scalp-based landmarks. Neurotherapeutix uses functional imaging and patented technology to take an individualized approach to treatment targeting.

The process begins with resting-state functional magnetic resonance imaging (rsfMRI). This type of functional imaging measures patterns of activity throughout the brain while you are at rest. Those patterns can be analyzed to examine functional connectivity, or how activity in different areas of your brain is related over time.

Neurotherapeutix then uses patented computational brain mapping technology to analyze those connectivity patterns and identify individualized areas of interest based on your functional brain organization.

The fMRI analysis helps identify individualized treatment targets within the patient’s own brain anatomy. These selected treatment locations are uploaded into the neuronavigation system, allowing the clinical team to consistently position the TMS coil over the intended target with millimeter-level precision throughout treatment.

This creates an important distinction between personalized TMS vs. standard TMS. Rather than relying only on a standardized treatment location, Neurotherapeutix uses whole-brain functional imaging and computational analysis to determine where to deliver stimulation for each patient.

For someone with treatment-resistant depression, this approach provides another way to think about treatment after medication has not provided adequate relief.

Research continues to examine how connectivity-based targeting may influence TMS outcomes and how individual differences in functional brain organization may inform treatment.

When to consider fMRI-guided TMS therapy for treatment-resistant depression

fMRI-guided TMS therapy may be worth discussing with our care team when depression has not adequately improved with antidepressant treatment or when medication side effects make other approaches worth exploring.

Whether and when fMRI-guided TMS therapy is appropriate depends on your diagnosis, treatment history, medical history, medications and other individual factors.

A clinical evaluation is important because TMS therapy is not appropriate for everyone, and treatment decisions should be based on your specific circumstances.

fMRI-guided TMS therapy is non-invasive and does not require surgery or anesthesia. Patients can generally return to their usual activities after a session.

If you are wondering whether your treatment history could make TMS an appropriate next step, learning about candidacy for TMS therapy can help you prepare for a conversation with your treatment team.

Frequently asked questions

Have additional questions about treatment sessions, eligibility, side effects or the Neurotherapeutix approach? Explore our frequently asked questions about TMS therapy for more information.

What qualifies as treatment-resistant depression?

Treatment-resistant depression is commonly defined as depression that has not adequately improved after at least two antidepressant treatments despite adequate dose, duration and adherence.

However, there is no single universally accepted definition. Your clinician will consider your complete treatment history rather than relying only on the number of medications you have tried.

How common is treatment-resistant depression?

Treatment-resistant depression is relatively common. Contemporary research estimates that at least 30% of people with depression may meet the commonly used definition of inadequate response to two appropriate antidepressant treatments.

The exact percentage varies among studies because researchers and clinicians have not historically used one universal definition of TRD.

Can treatment-resistant depression be treated without medication?

Medication is not the only treatment option for depression that has been difficult to treat.

Depending on your clinical needs, treatment may include psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy or other approaches. Some patients may use non-medication treatments alongside medication rather than replacing it.

The appropriate approach depends on your diagnosis, previous treatment response, health history and individual needs.

Is fMRI-guided TMS therapy effective for treatment-resistant depression?

TMS is an established, non-invasive treatment option for major depressive disorder, including for patients whose depression has not adequately responded to antidepressant medication.

Treatment response varies from person to person, and no treatment can guarantee a particular outcome.

At Neurotherapeutix, fMRI-guided TMS therapy adds individualized functional brain imaging, computational brain mapping and neuronavigation to inform treatment targeting.

Rather than determining the treatment location using only standardized anatomical measurements, the approach uses information from your individual functional brain organization to guide where stimulation is delivered.

Get started with Neurotherapeutix

Treatment-resistant depression does not mean you have reached the end of your treatment options. It may mean it is time to look at your depression, your treatment history and your next steps differently.

Neurotherapeutix is the only clinic in the United States offering its patented fMRI-guided TMS approach, combining whole-brain functional imaging, computational brain mapping, individualized targeting and neuronavigation to personalize treatment.

If depression symptoms have continued despite previous treatment and you want to explore whether this approach may be appropriate for you, request an appointment with our team at our Upper East Side Manhattan clinic.

When a parent seems more forgetful, withdrawn, anxious, or simply less like themselves, it can be difficult to know what’s part of normal aging and what deserves a closer look.

Changes in mood, memory, concentration, and behavior can have many possible causes. Rather than making assumptions based on age or symptoms alone, a comprehensive evaluation can help families better understand what may be contributing to those changes.

For some adults and elderly, advanced functional brain imaging can add another layer of insight. At Neurotherapeutix, computational brain mapping helps our clinicians better understand patterns of brain function that may be relevant to treatment planning.

So, when is it worth exploring for an aging parent? Here’s what families should know.

What computational brain mapping can tell us

A traditional MRI provides detailed images of the brain’s physical structure. Functional MRI (fMRI) provides clinicians with insights into brain activity and how different areas of the brain communicate.

At Neurotherapeutix, we use resting-state functional MRI (rsfMRI) with patented computational brain mapping to evaluate these patterns of functional connectivity.

For an older adult experiencing changes in mood, memory, concentration, or behavior, this information can add to the clinical picture.

Computational brain mapping does not diagnose a condition on its own or replace a comprehensive medical or psychiatric evaluation. Instead, it provides additional information clinicians can consider when making treatment decisions.

When fMRI-guided TMS therapy is appropriate, the brain map can also be used to identify precise, individualized treatment targets rather than relying solely on a standard treatment location.

Changes that may be worth a closer look

Not every change is cause for concern, but if something feels noticeably different about your parent, it may be worth discussing with a qualified clinician.

You might notice changes such as:

• Increasing forgetfulness
• Difficulty concentrating
• Withdrawal from family, friends, or favorite activities
• Changes in mood or motivation
• Persistent anxiety
• Changes in sleep
• Mental fatigue or “brain fog”
• Difficulty keeping up with familiar daily activities

One challenge is that different conditions can sometimes produce similar symptoms. Depression and cognitive decline, for example, may both involve forgetfulness, low energy, difficulty concentrating, and changes in motivation.

That’s why these symptoms shouldn’t automatically be dismissed as aging or assumed to have a particular cause. The appropriate next step depends on your parent’s individual symptoms, medical history, and clinical evaluation.

How computational brain mapping can guide treatment

If your parent is a candidate for fMRI-guided TMS therapy, their brain map can help Neurotherapeutix identify where treatment should be focused.

TMS, or transcranial magnetic stimulation, is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain.

Traditional TMS typically relies on standard anatomical landmarks to determine treatment placement. Neurotherapeutix uses each patient’s functional brain imaging and patented computational brain mapping to identify precise treatment targets based on their individual brain activity and connectivity.

For an aging patient, this means treatment is informed by their own brain rather than a standard location associated with a diagnosis.

Before treatment begins, our clinicians also review relevant medical history, medications, implanted devices, and other factors to determine whether MRI and TMS therapy are appropriate.

What can your parent expect?

Knowing what actually happens during brain mapping and fMRI-guided TMS therapy can make an unfamiliar treatment feel much less intimidating.

During the brain mapping scan

Your parent will lie inside an MRI scanner while resting-state functional images are collected. There are no needles or ionizing radiation involved.

The scan gathers the data needed for computational brain mapping. Your parent’s Neurotherapeutix team will explain what to expect beforehand and answer any questions about preparing for the scan.

During fMRI-guided TMS therapy

If TMS therapy is recommended, your parent will remain awake during each treatment session. TMS does not require surgery, anesthesia, or sedation.

A TMS device is positioned on the head and delivers magnetic pulses to the treatment location identified for that patient.

Treatment schedules vary, so your parent’s clinicians will explain the recommended frequency and duration based on their individual treatment plan.

Questions to ask before moving forward

Advanced technology should have a clear clinical purpose. Before pursuing computational brain mapping or TMS therapy, you should understand why it’s being recommended and how the information will be used.

Consider asking:

• What could be contributing to my parent’s symptoms?
• Have other potential causes been evaluated?
• Why are you recommending computational brain mapping?
• What information could the scan provide?
• How could the results affect treatment decisions?
• Is my parent a candidate for fMRI-guided TMS therapy?
• What safety screening is required?
• What should we realistically expect from treatment?
• What will treatment involve?
• What are the costs?

Depending on your parent’s symptoms, a clinician may recommend other medical, psychiatric, or cognitive evaluations before or alongside advanced brain imaging.

The goal is to choose the evaluation and treatment approach that makes sense for your parent, not simply the most advanced option available.

Frequently asked questions

Is computational brain mapping safe for elderly?

Computational brain mapping at Neurotherapeutix uses data collected through resting-state functional MRI, which does not use ionizing radiation. MRI and TMS are not appropriate for everyone, however, so medical history and relevant safety factors are reviewed before proceeding.

Can computational brain mapping diagnose dementia?

No. Computational brain mapping and fMRI-based connectivity analysis are not stand-alone diagnostic tests for dementia or any specific neurodegenerative disease. Changes in memory, attention, or thinking can have many possible causes—including depression, anxiety, sleep disruption, medications, medical conditions, and neurodegenerative disorders—and require a comprehensive clinical evaluation.

However, fMRI may identify functional-connectivity patterns that extend beyond those commonly associated with depression. When interpreted alongside a patient’s symptoms, medical history, neurological examination, cognitive testing, and other appropriate studies, these findings may support further evaluation for a possible neurodegenerative process associated with cognitive decline.

Is there an age limit for fMRI-guided TMS therapy?

Age alone does not determine whether someone is an appropriate candidate for our services.

A clinician needs to consider the patient’s health history, symptoms, medications, previous treatments, implanted devices, and other relevant factors.

Will insurance cover computational brain mapping and TMS therapy?

Neurotherapeutix is a premier private clinic and operates on a self-pay basis rather than participating in insurance networks.

While we do not communicate with insurance companies directly, our team can provide detailed visit information, including superbills and relevant clinical records, for patients to submit to their insurer if they choose to pursue out-of-network reimbursement.

How do I know if my parent is a good candidate?

Start with a consultation. The Neurotherapeutix team can review your parent’s symptoms, medical history, previous treatments, and goals and determine whether additional evaluation or fMRI-guided TMS therapy may be appropriate.

Is computational brain mapping the right next step for your parent?

There isn’t one answer for every older adult.

For some patients, computational brain mapping may provide useful additional information that helps clinicians make more informed treatment decisions. For others, a different evaluation or treatment may be more appropriate.

That’s why Neurotherapeutix starts with the individual, not the technology.

As the only clinical practice in the United States offering patented computational brain mapping to personalize fMRI-guided TMS therapy, Neurotherapeutix brings together advanced functional brain imaging and experienced clinical evaluation to determine whether this approach may be appropriate for each patient.

If you’re concerned about changes in your parent’s mood, memory, concentration, or behavior, a consultation can help you better understand the options available.

Request an appointment with Neurotherapeutix in Manhattan to start the conversation.

Deciding to explore a new mental health treatment can bring up a lot of questions. Explaining that decision to the people closest to you can sometimes feel even more complicated.

Your family may be unfamiliar with computational brain mapping or fMRI-guided TMS therapy. They may wonder what the technology does, why you’re considering it, whether it’s safe, or how it differs from treatments you’ve already tried.

You don’t need to become an expert before starting the conversation. A simple explanation of what you’re considering, why you’re considering it, and what you hope to learn can give your family a better understanding of your decision.

If you’re still learning about your options, you can also explore our services before deciding which questions you want to discuss together.

Why these conversations can be difficult

Mental health treatment can be personal. Family members may have their own experiences, expectations, or concerns, and newer technologies can add another layer of uncertainty.

Sometimes hesitation comes from simply not understanding what terms like “brain mapping” or “TMS” mean.

A loved one may hear “brain stimulation” and imagine a much more invasive procedure. Others may wonder why another approach is necessary when medications, psychotherapy, or other treatments are already available.

It can help to remember that questions aren’t necessarily opposition. Often, they’re an attempt to understand something unfamiliar.

Instead of beginning with the science, start with your own experience. Explain what you’ve been dealing with, what you’ve already tried, and why you’re interested in learning about another option.

You might say: “I’ve been looking into another treatment option because I want to better understand what may work for me. It uses brain imaging to help guide treatment based on how my own brain is functioning.”

That gives your family a place to begin without overwhelming them with clinical terminology.

What is computational brain mapping treatment? A simple explanation

One of the easiest ways to explain computational brain mapping is to separate the imaging from the treatment.

At Neurotherapeutix, resting-state functional MRI (rsfMRI) is used in combination with patented computational brain mapping to examine patterns of brain activity and how different areas of the brain communicate.

Think of the brain map as information. It gives our clinicians a more detailed picture of your individual brain function that can be considered alongside your symptoms, history, previous treatments, and clinical evaluation.

The map itself is not a treatment.

When clinically appropriate, those insights can then be used to help identify precise treatment targets for fMRI-guided TMS therapy.

TMS, or transcranial magnetic stimulation, is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. Standard TMS therapy typically uses general anatomical landmarks to determine treatment placement. Neurotherapeutix uses each patient’s functional brain data to help determine where treatment should be focused.

A simple way to explain the process to your family is: “The scan helps my doctors understand how different areas of my brain are communicating. If TMS therapy is right for me, they can use that information to identify a precise treatment target.”

That’s usually enough information for a first conversation. You can always go deeper into the science later.

Explaining the benefits to a loved one

When talking with family, focus less on how sophisticated the technology is and more on why having additional information matters to you.

You may be interested in computational brain mapping because previous treatments haven’t provided sufficient relief.

You may want to understand all of your options before making another treatment decision.

Or you may value an approach that considers information from your individual brain rather than relying only on a diagnosis.

The important distinction is that Neurotherapeutix doesn’t use computational brain mapping simply to create an image of the brain. The information has a clinical purpose: when TMS therapy is appropriate, it can help clinicians identify precise, individualized treatment targets.

Learning more about how computational brain mapping personalizes TMS therapy may also help your family understand why you’re considering this approach.

Try keeping the conversation centered on your reason for exploring it: “I’m not committing to a treatment just because the technology is advanced. I’m interested because it may give my doctors more information to make a treatment decision based on my individual brain.”

That distinction can be especially helpful for family members who are skeptical of treatments they haven’t encountered before.

Addressing common questions and concerns

Questions are a normal part of considering any treatment. You don’t need to have every answer yourself, but understanding a few basics can make the conversation easier.

Is it safe?

Computational brain mapping at Neurotherapeutix uses functional MRI. MRI uses magnetic fields and radio waves to create images and does not expose patients to ionizing radiation.

The mapping process itself gathers information. It does not stimulate or alter the brain.

TMS therapy is a separate process. It is non-invasive and does not require surgery, anesthesia, or sedation. Before either MRI or TMS therapy is recommended, clinicians consider medical history and relevant safety factors to determine whether the procedure is appropriate.

Research also supports the use of functional brain imaging to help individualize TMS treatment targets.

In a 2025 study of patients with treatment-resistant depression, researchers used each patient’s fMRI connectivity data to personalize the stimulation site and reported significant reductions in depression symptoms following treatment.

Will treatment change who they are?

This concern may come up when a family first hears terms such as “computational brain mapping” or “brain stimulation.”

Computational brain mapping does not change the brain or a person’s personality. It collects information about brain activity and connectivity that clinicians can use as part of treatment planning.

If your family is asking about TMS therapy, explain that the goal is not to change who someone is. TMS is used to stimulate specific areas of the brain associated with the condition being treated.

For patients receiving other forms of treatment as well, learning about combining computational brain mapping with psychotherapy can help families understand how different elements of a treatment plan may work together.

What does fMRI-guided TMS therapy involve?

If fMRI-guided TMS therapy is recommended, treatment takes place over a series of sessions.

During each session, the patient remains awake while a TMS device positioned on the head delivers magnetic pulses to the treatment area. There is no surgery or anesthesia, and patients can typically return to their regular activities after a session.

The recommended treatment schedule depends on the individual patient, condition, and treatment plan. Your Neurotherapeutix clinician can explain what to expect based on your specific circumstances.

Supporting a loved one through treatment

Family support doesn’t require understanding every detail of the technology.

Often, the most valuable thing you can do is listen.

Ask your loved one what kind of support would actually be useful. They may appreciate help getting to appointments, someone to talk with afterward, or simply knowing that they don’t have to continually explain or defend their treatment decision.

Try not to monitor every good or bad day as evidence that treatment is or isn’t working. Response to fMRI-guided TMS therapy can vary, and progress should be evaluated with the clinical team over time.

You can also learn more together about how fMRI-guided TMS therapy fits into a holistic mental health plan, particularly if your loved one is also participating in psychotherapy, psychiatric care, medication management, or other forms of support.

Most importantly, allow the person receiving treatment to remain at the center of the decision. Being involved doesn’t mean taking over. It means helping them feel informed, respected, and supported.

Frequently asked questions

How do I bring up computational brain mapping treatment with a resistant family member?

Start with why you’re considering it rather than trying to convince them of the technology.

You might explain what you’ve already tried, what you’re hoping to improve, and why having more individualized information about your brain is meaningful to you.

If they have concerns you can’t answer, write the questions down and bring them to your consultation. You don’t need to resolve every concern in one conversation.

What role can family play during fMRI-guided TMS therapy?

That depends on what the person receiving treatment wants.

Family members may help with transportation, appointments, practical responsibilities, or simply emotional support. They can also help keep track of questions to discuss with the clinical team.

The most helpful approach is usually to ask rather than assume what kind of involvement is wanted.

Where can my family learn more before deciding?

Start with reliable medical information and the specific treatment information provided by your clinical team.

Neurotherapeutix can explain how computational brain mapping and fMRI-guided TMS therapy are used within our practice, while independent organizations such as the National Institute of Mental Health provide broader educational information about brain stimulation therapies.

Your family can also review the Neurotherapeutix services together and bring any questions to an initial consultation.

Make the decision together, without losing sight of who it’s for

Family can be an important source of support when you’re considering a new treatment, but ultimately, the decision should center on the person receiving it.

Give everyone room to ask questions. Learn about the technology together. Talk openly about your concerns and expectations. And rely on qualified clinicians to help you understand what is and isn’t appropriate for your individual situation.

Neurotherapeutix is the only clinical practice in the United States offering patented computational brain mapping to personalize fMRI-guided TMS therapy.

Our Manhattan team uses advanced functional brain imaging alongside comprehensive clinical evaluation to help determine whether this approach may be appropriate for you.

Learn more about TMS therapy in Manhattan and the treatment options available at Neurotherapeutix, or request an appointment to start the conversation.

When someone you love is considering treatment for depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), or another neurological or psychiatric condition, it’s natural to have questions. You want to understand what the treatment involves, whether it’s safe, and how you can best support them through an important healthcare decision.

At Neurotherapeutix, fMRI-guided TMS therapy combines advanced neuroscience with personalized care to develop treatment plans tailored to each patient’s unique brain connectivity.

Rather than relying on standardized treatment locations, our team uses patented computational brain mapping to better understand how different brain networks communicate before treatment begins.

You don’t need to become an expert in neuroscience to support someone you care about. This guide explains how treatment works, what your loved one can expect throughout the process, and the important role family members can play at every step.

Why this guide is for you, not just your loved one

A mental health or neurological diagnosis rarely affects just one person. Partners, parents, children, siblings, and close friends often become an important part of the treatment journey.

You may be the person helping your loved one research treatment options, attending appointments, providing transportation, or simply offering encouragement on difficult days.

Having a basic understanding of how personalized brain-based treatment works can make those conversations feel less overwhelming and help you provide more meaningful support.

It’s also normal to feel uncertain when you hear unfamiliar terms like functional MRI, brain connectivity, or computational brain mapping. While these concepts sound highly technical, their purpose is straightforward: to help clinicians better understand how an individual’s brain functions so treatment can be tailored to the person, not just the diagnosis.

At Neurotherapeutix, families are encouraged to ask questions, participate in discussions when appropriate, and feel confident about the treatment decisions being made together.

What is fMRI-guided brain mapping?

One of the most common questions families ask is, “What exactly is brain mapping?”

At Neurotherapeutix, how personalized brain mapping works begins with resting-state functional MRI (rsfMRI), a specialized type of functional MRI that measures how different regions of the brain communicate while a person is at rest.

Unlike a standard MRI, which produces images of the brain’s anatomy, rsfMRI measures functional connectivity—the communication patterns among networks involved in mood, attention, memory, emotional regulation, and other important functions.

Those connectivity patterns are then analyzed using Neurotherapeutix’s patented computational brain mapping technology.

Instead of assuming every patient with the same diagnosis should receive identical treatment, our clinicians evaluate each person’s unique brain network activity alongside their symptoms, medical history, and treatment goals. This additional layer of information helps guide a more personalized treatment strategy.

The MRI itself is non-invasive and does not use ionizing radiation, making it a well-established medical imaging technology used for decades.

For families, the most important takeaway is this: computational brain mapping isn’t performed simply to create another scan. It’s used to better understand how your loved one’s brain functions before treatment begins.

How this approach differs from standard TMS therapy

If you’ve researched TMS therapy before, you may wonder why Neurotherapeutix’s approach is different.

Traditional TMS therapy has helped many people living with treatment-resistant psychiatric conditions. In most settings, however, treatment targets are selected using standardized anatomical landmarks that are designed to work for the average patient.

Neurotherapeutix takes a more individualized approach.

Rather than relying solely on generalized measurements, our clinicians use functional connectivity data obtained through rsfMRI and patented computational brain mapping to better understand how each patient’s brain networks communicate. That information is combined with a comprehensive psychiatric evaluation before treatment begins.

This means treatment planning is informed by the individual rather than a standardized protocol.

If you’d like to understand the differences in greater detail, our comparison of personalized TMS therapy vs. standard TMS therapy explains how individualized targeting differs from traditional approaches.

For many families, this additional level of personalization provides reassurance that treatment planning is based on their loved one’s unique clinical presentation rather than a one-size-fits-all model.

Who may benefit from this approach?

Many patients receiving care at Neurotherapeutix are being treated for conditions such as depression, PTSD, anxiety disorders, OCD, and other neurological or psychiatric conditions.

In fact, many individuals who pursue fMRI-guided TMS therapy have also experienced treatment-resistant depression (TRD), meaning their symptoms have not adequately improved after trying at least two antidepressant medications at appropriate doses and durations.

According to the National Institute of Mental Health, treatment-resistant depression is one reason clinicians may consider brain stimulation therapies as part of a comprehensive treatment plan when other approaches have not provided sufficient relief.

Whether your loved one is seeking care for treatment-resistant depression or another neurological or psychiatric condition, every patient’s treatment journey begins with a comprehensive clinical evaluation to determine the most appropriate, individualized approach.

What to expect during the treatment process

Knowing what lies ahead can make the treatment process feel much less intimidating for both patients and their families.

The initial consultation and brain scan

Every patient’s journey begins with a comprehensive clinical evaluation.

During this appointment, the clinical team reviews symptoms, medical history, previous treatments, medications, and treatment goals.

Resting-state fMRI (rsfMRI) imaging is performed so clinicians can evaluate functional brain connectivity before developing a personalized treatment plan.

This evaluation allows the team to determine whether fMRI-guided TMS therapy is appropriate and how treatment can best be individualized.

The treatment sessions

Once treatment begins, your loved one will attend a series of scheduled TMS therapy sessions.

Because TMS therapy is non-invasive, patients remain awake throughout treatment and can typically return to many normal daily activities afterward.

Unlike treatments that require anesthesia or sedation, patients are able to drive themselves to and from most appointments unless their physician recommends otherwise.

Each treatment session follows the personalized plan developed during the initial evaluation and computational brain mapping, allowing stimulation to be guided by the individual’s unique brain connectivity rather than standardized anatomical landmarks.

Monitoring progress over time

Treatment doesn’t stop after the first session.

Throughout care, Neurotherapeutix’s multidisciplinary team continues monitoring symptoms, overall well-being, and clinical progress.

Psychiatric evaluations, patient feedback, and ongoing clinical observations help ensure treatment remains aligned with each person’s needs.

Families often play an important role during this phase by noticing changes in mood, daily functioning, motivation, sleep, or engagement in everyday activities that their loved one may not immediately recognize themselves.

How family members can offer meaningful support

While every treatment journey is unique, the support of family and close friends can make a meaningful difference. You don’t need to have all the answers to help your loved one feel encouraged and understood.

Listen before trying to solve the problem

Many people seeking fMRI-guided TMS therapy have spent months—or even years—trying medications, psychotherapy, or other treatments before exploring a more personalized approach.

Rather than feeling pressure to offer solutions, one of the most valuable things you can do is listen without judgment and acknowledge what they’ve been through.

Giving your loved one space to share their concerns, hopes, or frustrations can help them feel supported throughout the decision-making process.

Learn about the treatment together

Understanding the basics of treatment can make conversations with your loved one—and their care team—more productive.

If appropriate, consider attending the initial consultation, asking questions about the evaluation process, and learning how personalized treatment planning differs from conventional approaches.

Feeling informed often helps families feel more confident and better prepared to support treatment decisions.

Support the routine

fMRI-guided TMS therapy involves a series of scheduled treatment sessions over several weeks. Helping your loved one maintain that routine can reduce stress throughout treatment.

Depending on their needs, support may include:

• Providing transportation to appointments
• Helping coordinate work or family schedules
• Assisting with childcare or household responsibilities
• Encouraging consistency with treatment appointments
• Offering emotional encouragement throughout the process

These practical forms of support often allow patients to focus more fully on their care.

Celebrate progress—even when it’s gradual

Improvement doesn’t always happen all at once.

Some people notice small changes first, such as improved concentration, better sleep, increased motivation, or greater participation in daily activities, before larger improvements become apparent.

Recognizing these milestones together can help reinforce progress and encourage continued engagement with treatment.

Common questions families ask before starting treatment

It’s completely normal to have questions before a loved one begins a new treatment approach. Many families want reassurance that they’re making an informed decision and understand what to expect moving forward.

Some of the most common questions include:

• Is this treatment safe?
• How is personalized brain mapping different from a standard MRI?
• Will my loved one need to stop taking their medications?
• How long does treatment typically last?
• What kinds of conditions may benefit from this approach?

During the consultation process, Neurotherapeutix’s clinical team takes time to answer these questions and explain each step of the evaluation and treatment process.

Families are encouraged to ask questions and participate in discussions whenever appropriate.

Frequently asked questions

Is fMRI-guided TMS therapy safe?

Yes, fMRI-guided TMS therapy is typically considered a safe, non-invasive treatment that combines advanced brain imaging with transcranial magnetic stimulation to personalize treatment planning.

MRI technology does not use ionizing radiation, and TMS therapy is an established, evidence-based treatment for several neurological and psychiatric conditions when recommended by a qualified clinician.

Will my loved one need to stop their medications?

Not necessarily. Every treatment plan is individualized. During the initial evaluation, the clinical team reviews current medications and determines whether any adjustments are appropriate.

Patients should never stop taking prescribed medications without guidance from their treating physician.

How can I tell if treatment is working?

Progress looks different for every individual. Some people first notice subtle improvements, such as better concentration, increased motivation, improved sleep, or greater emotional resilience, before larger changes become apparent.

Throughout treatment, Neurotherapeutix’s multidisciplinary team continually monitors progress and adjusts care based on each patient’s clinical response.

Who may benefit from fMRI-guided TMS therapy?

fMRI-guided TMS therapy may be appropriate for individuals experiencing depression, anxiety disorders, OCD, PTSD, ADHD, autism spectrum disorder, traumatic brain injury (TBI), migraine headaches, cognitive concerns, and other neurological or psychiatric conditions.

Eligibility is always determined through a comprehensive clinical evaluation.

Taking the next step together

Choosing a new treatment approach can feel overwhelming, but you don’t have to navigate it alone.

By understanding how personalized brain mapping and fMRI-guided TMS therapy work, families can play an important role in supporting a loved one’s treatment journey with confidence and compassion.

Whether you’re exploring options for the first time or looking for a more individualized approach after previous treatments, Neurotherapeutix is here to answer your questions and help you make informed decisions together.

When you’re ready, you can request an appointment to meet with our clinical team and learn whether personalized, brain-based care may be the right next step for your loved one.

Watching someone you love struggle with depression, anxiety, post-traumatic stress disorder (PTSD), or another neurological or psychiatric condition can be incredibly difficult, especially when they aren’t ready to seek help.

Sometimes the hesitation comes from discouragement after trying medications or therapy without meaningful improvement.

Other times it’s fear of the unknown, concerns about side effects, or simply feeling exhausted by the idea of trying yet another treatment.

At Neurotherapeutix, fMRI-guided TMS therapy offers a different approach.

Rather than relying solely on standardized treatment protocols, our clinicians use patented computational brain mapping to better understand how an individual’s brain networks communicate before treatment begins. For many families, knowing that treatment is personalized—not one-size-fits-all—can make the conversation feel less overwhelming.

If someone you care about has been reluctant to seek treatment, understanding this approach may help you support them with empathy, information, and hope.

Understanding why a loved one might resist treatment

When someone refuses treatment, it’s easy to assume they simply don’t want help.

In reality, reluctance often comes from a much more complicated place.

Some people have spent years trying medications, psychotherapy, or other interventions without experiencing the improvement they hoped for.

Others worry about being judged, feel discouraged after previous setbacks, or believe nothing will make a meaningful difference.

Mental health conditions themselves can also make it harder to seek care:

• Depression may reduce motivation and make even simple decisions feel overwhelming.
• Anxiety can amplify fears about starting something unfamiliar.
• PTSD may lead someone to avoid situations that feel emotionally vulnerable.

According to the National Institute of Mental Health, depression can affect how a person thinks, feels, and manages daily activities, making it difficult to seek help even when support is available.

Recognizing these barriers doesn’t solve them overnight, but it can change how families approach the conversation. Rather than viewing hesitation as resistance, it can help to see it as uncertainty, discouragement, or fear rooted in previous experiences.

That understanding creates space for a different discussion—one focused on exploring options instead of convincing someone to accept treatment.

Why a personalized approach may feel different

For many people, the idea of trying another treatment feels discouraging because previous approaches haven’t provided lasting improvement.

That’s one reason Neurotherapeutix takes a different approach.

Rather than beginning with a standardized treatment location, our clinicians first evaluate how an individual’s brain functions using brain mapping technology, which combines resting-state functional MRI (rsfMRI) with patented computational brain mapping.

This advanced imaging evaluates functional connectivity—the communication patterns between different brain networks involved in mood, attention, memory, emotional regulation, and other important functions.

Instead of assuming every patient with the same diagnosis should receive identical treatment, our team develops a personalized treatment plan based on each person’s symptoms, medical history, treatment goals, and unique brain connectivity.

For many families, this individualized approach feels different because it begins with understanding the person rather than simply applying the same protocol used for every patient.

It’s also important to remember that learning more about treatment doesn’t obligate anyone to begin therapy. An evaluation is simply an opportunity to gather information, ask questions, and determine whether this personalized approach may be appropriate.

How computational brain mapping works, step by step

One of the biggest sources of hesitation is simply not knowing what to expect. Understanding the process can help reduce some of that uncertainty and make the first conversation about treatment feel less intimidating.

The brain scan

Every patient’s journey begins with a comprehensive clinical evaluation.

During this appointment, the clinical team reviews symptoms, medical history, previous treatments, medications, and treatment goals.

When clinically appropriate, resting-state functional MRI is performed to evaluate how different brain regions communicate while the brain is at rest.

Unlike a traditional MRI, which produces images of the brain’s anatomy, rsfMRI measures functional connectivity to provide additional insight into how the brain’s networks function together.

Personalized treatment planning

After imaging is completed, the functional connectivity data is analyzed using Neurotherapeutix’s patented computational brain mapping technology.

Rather than relying solely on generalized anatomical landmarks, clinicians combine this information with the patient’s psychiatric evaluation, symptoms, medical history, and treatment goals to develop an individualized treatment plan.

Every recommendation is made on a case-by-case basis because no two brains—or treatment journeys—are exactly alike.

Non-invasive TMS therapy sessions

If treatment is recommended, patients receive TMS therapy in Manhattan according to their individualized treatment plan.

Because TMS therapy is non-invasive, patients remain awake throughout treatment and can typically return to many normal daily activities afterward.

Unlike procedures that require anesthesia or sedation, most individuals can drive themselves to and from appointments unless their physician recommends otherwise.

Throughout treatment, the clinical team continues monitoring progress, symptoms, and overall well-being while making recommendations based on each patient’s individual response.

Conditions where this approach may help

Every person’s experience is unique, and eligibility for treatment is determined through a comprehensive clinical evaluation. However, computational brain mapping and fMRI-guided TMS therapy may be considered for a variety of neurological and psychiatric conditions when clinically appropriate.

Depression

Many families begin exploring new options after watching a loved one struggle with depression despite previous treatment.

TMS therapy is FDA-cleared for the treatment of major depressive disorder in appropriate patients, and Neurotherapeutix combines this established therapy with patented computational brain mapping to personalize treatment planning based on each individual’s unique brain connectivity.

Anxiety

For individuals living with anxiety, brain networks involved in emotional regulation and stress responses may function differently from one person to another. Personalized treatment planning helps clinicians better understand those individual differences before developing a treatment approach.

PTSD

Living with post-traumatic stress disorder can affect emotional regulation, memory, concentration, and everyday functioning.

According to the U.S. Department of Veterans Affairs National Center for PTSD, effective treatment often begins with a comprehensive evaluation to better understand each person’s symptoms and experiences.

At Neurotherapeutix, individualized treatment planning considers the patient’s clinical history alongside advanced functional imaging to help guide care.

Although these are among the most common conditions treated, every recommendation is based on each individual’s symptoms, treatment history, and overall clinical evaluation.

How to talk to a loved one who is hesitant

Supporting someone who is reluctant to seek treatment can be challenging. While you may want to encourage them to get help, trying to persuade or pressure them often has the opposite effect.

Instead, focus on creating a conversation that feels supportive rather than convincing.

Start with curiosity instead of persuasion

Rather than telling your loved one what they should do, consider asking open-ended questions such as:

• “Can you tell me what’s making you hesitant?”
• “What concerns you most about treatment?”
• “Is there anything about previous treatments that makes you unsure about trying something new?”

Listening without immediately offering solutions helps your loved one feel heard and respected.

Acknowledge what’s already been difficult

Many people considering fMRI-guided TMS therapy have already spent months—or even years—trying medications, psychotherapy, or other interventions.

Recognizing those experiences can help your loved one feel understood. Sometimes simply acknowledging, “I know you’ve been through a lot already,” is more meaningful than trying to solve the problem right away.

Focus on learning, not committing

One of the biggest misconceptions families have is believing that scheduling a consultation means committing to treatment.

Instead, remind your loved one that an initial evaluation is an opportunity to ask questions, learn about personalized treatment options, and determine whether fMRI-guided TMS therapy may be appropriate.

Gathering information doesn’t obligate anyone to move forward.

Let them stay in control

Ultimately, treatment decisions belong to your loved one.

Your role isn’t to make the decision for them—it’s to provide encouragement, help them explore options, and remind them that support is available whenever they’re ready.

Frequently asked questions

Is brain mapping the same as standard TMS therapy?

No. Standard TMS therapy typically uses standardized anatomical landmarks to identify treatment locations.

At Neurotherapeutix, patented computational brain mapping uses resting-state functional MRI to evaluate each patient’s unique brain connectivity before treatment planning begins, allowing for a more personalized approach.

Does my loved one need a referral to get started?

No. Patients can schedule a consultation directly. During the initial evaluation, the clinical team reviews symptoms, medical history, prior treatments, and treatment goals to determine whether fMRI-guided TMS therapy is appropriate.

What if they’ve tried treatment before without success?

Previous treatment experiences don’t necessarily determine future options.

Many patients who seek care at Neurotherapeutix have tried medications, psychotherapy, or other interventions before exploring personalized brain-based treatment.

Every recommendation is individualized based on a comprehensive clinical evaluation.

Does insurance cover this treatment?

Neurotherapeutix is a private-pay practice. While the clinic does not communicate directly with insurance companies, patients who choose to pursue out-of-network reimbursement may receive superbills and supporting documentation to submit independently. The clinical team can also answer questions about the evaluation process and associated costs during your consultation.

Helping your loved one take the first step

Watching someone you care about struggle with their mental health or a neurological condition can leave you feeling helpless. While you can’t make the decision for them, you can offer support, understanding, and reliable information as they consider their options.

Sometimes the hardest part isn’t beginning treatment—it’s taking the first step toward learning what’s possible.

If your loved one is ready to explore a more personalized approach, Neurotherapeutix is here to answer your questions and explain how individualized treatment planning may fit their unique needs.

To get started, request an appointment to begin the conversation with our clinical team.

For many people living with depression, anxiety, obsessive-compulsive disorder (OCD), or other mental health conditions, treatment begins with medication. While medication can be an important part of care, finding the right option is not always straightforward.

It is common for patients to spend months—or even years—adjusting dosages, switching prescriptions, or trying different combinations before finding meaningful improvement. This process is not a reflection of the patient’s effort or the physician’s expertise. Rather, it reflects the reality that every brain functions differently.

Computational brain mapping offers a different starting point.

Instead of relying primarily on symptom observation and medication response over time, Neurotherapeutix begins by evaluating how brain networks communicate.

Using advanced functional imaging and patented computational brain mapping, our team develops individualized treatment plans designed around each patient’s unique connectivity patterns.

This information can then be used to guide fMRI-guided TMS therapy and other treatment decisions, creating a more personalized path forward for individuals who feel stuck in a cycle of trial and error.

When medication becomes a process of elimination

Medication remains one of the most common treatments for depression and other mental health conditions.

For many individuals, it can provide meaningful symptom relief and improve quality of life.

However, medication management is often a process of refinement rather than immediate precision.

How medication management typically works

When a patient begins treatment, clinicians make recommendations based on symptoms, diagnosis, medical history, and clinical experience.

From there, treatment often involves:

• Starting a medication
• Monitoring response
• Adjusting dosage
• Evaluating side effects
• Trying alternatives when necessary

Because individuals respond differently to medications, it can take time to determine which option is the best fit.

Why it can take months—or years—to find the right fit

Mental health medications typically require several weeks before their full effects can be evaluated.

If symptoms do not improve, adjustments may be needed. Sometimes the medication works partially. Sometimes side effects become problematic. Sometimes another medication is added or substituted.

Over time, this process may involve multiple treatment attempts.

For patients who have already spent months or years navigating medication changes, the experience can become frustrating and emotionally exhausting.

For example, according to the National Institute of Mental Health, major depression affects millions of adults each year, and many individuals require multiple treatment attempts before finding an approach that provides meaningful symptom improvement.

This reality helps explain why medication management can become a lengthy process of adjustment and observation rather than a straightforward path to relief.

What “treatment-resistant” actually means

The term treatment-resistant depression generally refers to depression that has not adequately improved after multiple appropriate treatment attempts.

This does not mean a person cannot improve.

Instead, it often indicates that additional treatment approaches may be needed.

For many individuals seeking treatment for depression, persistent symptoms despite medication can become the reason they begin exploring alternatives such as functional brain imaging and fMRI-guided TMS therapy.

What brain mapping adds to the picture

Computational brain mapping is not a replacement for medication.

Rather, it provides an additional layer of information that can help clinicians better understand how a patient’s brain networks function.

Instead of focusing solely on symptoms, brain mapping evaluates the communication patterns occurring beneath those symptoms.

How fMRI-based imaging identifies functional connectivity patterns

At Neurotherapeutix, the process begins with patented computational brain mapping supported by advanced rsfMRI imaging.

Resting-state functional MRI measures blood oxygen level-dependent (BOLD) signals while the brain is at rest. These signals help reveal how different regions of the brain communicate within larger functional networks.

Rather than examining brain anatomy alone, the imaging evaluates functional connectivity—the relationships between neural systems involved in mood regulation, emotional processing, cognition, attention, and behavior.

What the data shows about individual brain differences

Two people may receive the same diagnosis while experiencing very different underlying network patterns.

One patient with depression may demonstrate connectivity changes involving emotional regulation circuits. Another may show disruptions involving cognitive control networks.

These differences help explain why individuals can respond differently to the same treatment.

Computational brain mapping allows clinicians to move beyond diagnosis alone and evaluate how a specific patient’s brain functions.

Why one-size-fits-all approaches may miss the mark

Traditional treatment approaches often begin with what is most likely to help based on population-level data.

Computational brain mapping starts with information about the individual.

This does not eliminate clinical judgment or replace other forms of treatment. Instead, it provides additional insight that may support more personalized decision-making.

From imaging to treatment planning

Collecting imaging data is only the beginning.

The value comes from how that information is translated into individualized treatment planning.

How rsfMRI findings inform stimulation targeting

After imaging is completed, Neurotherapeutix’s patented computational brain mapping platform analyzes functional connectivity patterns throughout the brain.

This analysis helps identify:

• Underactive networks
• Overactive networks
• Connectivity disruptions
• Neural circuits associated with symptoms

The goal is to understand how the patient’s brain networks communicate and where intervention may be most appropriate.

Targeting circuits tied to a patient’s specific symptoms

Once connectivity patterns have been analyzed, clinicians can use that information to help guide treatment planning.

For patients pursuing fMRI-guided TMS therapy, imaging data helps identify individualized stimulation targets based on network function rather than generalized positioning methods.

This approach recognizes that symptoms arise from neural circuits, not simply diagnoses.

How the approach differs from generalized anatomical landmarks

Standard TMS therapy protocols often rely on anatomical landmarks to determine stimulation locations.

Neurotherapeutix takes a different approach.

Using computational brain mapping and rsfMRI findings, clinicians evaluate where symptom-related networks are functioning within that patient’s brain before treatment begins.

This allows for individualized targeting based on functional connectivity rather than solely on anatomical assumptions.

What this means for the treatment timeline

One of the most common questions patients ask is whether brain mapping prolongs the treatment process.

The answer depends on how the timeline is measured.

Consultation and computational brain mapping before treatment begins

An fMRI-guided approach involves additional evaluation before treatment starts.

Patients first complete consultations, imaging, and computational analysis before individualized treatment planning occurs.

This requires more upfront assessment than simply beginning a medication trial.

Ongoing monitoring and targeting adjustments

The additional information gathered at the beginning may help support more informed treatment decisions moving forward.

Rather than relying exclusively on symptom response to guide adjustments, clinicians can incorporate connectivity data and individualized treatment planning into the decision-making process.

When to consider this approach

Many patients explore brain mapping after:

• Multiple medication trials
• Partial improvement from medications
• Persistent symptoms
• Previous standard TMS therapy
• Interest in a more personalized treatment strategy

For these individuals, understanding how their brain networks function may provide useful information when considering next steps.

Taking a closer look at your brain

If you have spent years navigating medication changes, dosage adjustments, or treatment approaches that did not provide the improvement you hoped for, it may feel as though you have run out of options.

In reality, you may simply need more information.

Computational brain mapping offers a way to evaluate how your brain networks function before making treatment decisions. At Neurotherapeutix, this information helps guide individualized care using advanced functional imaging, connectivity analysis, and fMRI-guided TMS therapy.

As the only clinical practice in the United States offering patented fMRI-guided TMS therapy and computational brain mapping, Neurotherapeutix provides a uniquely personalized approach designed around how your brain actually functions.

If you are interested in learning whether this approach may be appropriate for you, request an appointment to speak with our team.

Frequently asked questions

How is computational brain mapping different from a standard psychiatric evaluation?

A standard psychiatric evaluation focuses on symptoms, medical history, treatment history, and clinical assessment.

Computational brain mapping adds objective functional imaging data that helps clinicians evaluate how brain networks communicate and how those patterns may relate to symptoms.

Can computational brain mapping be used alongside medication?

Yes. Computational brain mapping does not replace medication. In many cases, it may be used alongside medication management, psychotherapy, or other treatment approaches as part of a comprehensive treatment plan.

Is fMRI-guided TMS therapy right for me if I’ve tried antidepressants without success?

It may be appropriate for some individuals who have not experienced adequate improvement from medication alone. Eligibility is determined through a clinical evaluation that considers symptoms, treatment history, and overall health.

Does Neurotherapeutix accept insurance?

Neurotherapeutix is a private-pay practice. We do not submit claims, communicate with insurance companies, or manage reimbursement requests on behalf of patients. However, we provide visit documentation, clinical records, and billing information for patients who choose to pursue reimbursement independently.

How do I get started?

The first step is a consultation. During the evaluation process, clinicians review your symptoms, treatment history, and goals to determine whether computational brain mapping and fMRI-guided TMS therapy may be appropriate for your needs.

Additional answers to common questions can also be found in our FAQ resources.

The effectiveness of brain stimulation depends on more than the stimulation itself. It also depends on where that stimulation is delivered.

Standard transcranial magnetic stimulation (TMS) therapy and fMRI-guided TMS therapy use the same non-invasive technology, but they approach treatment planning very differently.

A standard approach relies on fixed anatomical landmarks based on population averages, whereas an individualized approach uses each patient’s functional brain imaging and connectivity data to identify person‑specific treatment targets.

Understanding that distinction can help answer an important question: Why does precision matter?

At Neurotherapeutix, our approach begins with fMRI-guided TMS therapy, using functional connectivity data to guide individualized treatment planning.

As the only clinical practice in the United States offering patented fMRI-guided TMS therapy and computational brain mapping, we believe understanding where stimulation is delivered is just as important as the stimulation itself.

What is standard TMS therapy and how does it work?

Standard TMS therapy has helped expand access to non-invasive brain stimulation and has become an established treatment option for several mental health conditions.

According to the National Institute of Mental Health, TMS therapy uses magnetic pulses to stimulate specific areas of the brain involved in mood, cognition, and emotional regulation. It is commonly used when symptoms have not adequately improved with first-line treatments.

Understanding how standard TMS therapy works provides an important foundation for understanding how fMRI-guided approaches differ.

The mechanism: magnetic pulses and cortical stimulation

TMS therapy uses a magnetic coil positioned against the scalp to generate focused magnetic pulses.

These pulses pass through the skull and influence activity within targeted brain circuits. Over time, repeated stimulation may help support neuroplasticity, the brain’s ability to strengthen and reorganize neural connections.

Patients remain awake during treatment and can typically return to normal daily activities afterward.

Understanding how TMS therapy works provides useful context for comparing standard and connectivity-guided approaches.

How targets are selected in standard protocols

Most standard TMS therapy protocols identify treatment targets using scalp measurements and generalized anatomical landmarks.

For example, clinicians may approximate a stimulation site in the dorsolateral prefrontal cortex using scalp measurements or established positioning formulas. These methods are widely used and supported by clinical research, but they rely on external head measurements and group‑average data rather than the patient’s own brain anatomy, so the actual stimulation site can be substantially off and may not even fall fully within the true dorsolateral prefrontal region.

In practice, this means a fixed anatomical spot on the scalp is treated as if it reliably corresponds to the intended cortical target, even though it does not guarantee that stimulation reaches the same brain region or functional network in every patient..

The challenge is that both brain structure and connectivity can differ from person to person, so a ‘standard’ scalp location can map to different underlying tissue and network organization across patients. This variability is one reason Neurotherapeutix focuses on fMRI‑guided, personalized targeting that is based on each patient’s own brain networks rather than generalized anatomical assumptions.

What FDA clearance for standard TMS therapy covers

FDA-cleared TMS therapy protocols have demonstrated effectiveness for several conditions and have helped expand access to non-invasive brain stimulation.

Today, repetitive transcranial magnetic stimulation (rTMS) is FDA-cleared for:

• Treatment-resistant depression
• Obsessive-compulsive disorder (OCD)
• Migraines
• Anxiety symptoms associated with depression
• Smoking dependence

However, TMS therapy does not produce the same therapeutic effects as electroconvulsive therapy (ECT), and it is not approved for children younger than 15 years old.

These clearances are based on standardized treatment approaches that have helped many patients.

The question is not whether standard TMS therapy works. It clearly can.

The question is whether a more individualized understanding of brain connectivity may help improve how treatment targets are selected.

What “fMRI-guided” means in practice

The term “fMRI-guided” refers to the use of functional magnetic resonance imaging (fMRI) to help determine where stimulation should be delivered.

Instead of relying solely on anatomical estimates, clinicians evaluate how brain networks communicate and use that information to guide treatment planning.

This is where Neurotherapeutix differs from traditional TMS providers.

Resting-state fMRI and functional connectivity mapping

At Neurotherapeutix, treatment begins with advanced imaging.

Resting-state functional MRI (rsfMRI) measures blood oxygen level-dependent (BOLD) signals while the brain is at rest. These signals help reveal how different brain regions communicate within larger functional networks.

Rather than simply identifying where structures are located, rsfMRI helps clinicians understand how neural systems interact.

This information serves as the foundation of our patented computational brain mapping process, which analyzes functional connectivity patterns across the brain to identify individualized treatment targets.

From imaging to individualized targeting coordinates

Once imaging data is collected, Neurotherapeutix’s patented computational brain mapping platform performs advanced analysis of connectivity patterns throughout the brain.

Clinicians can identify:

• Underactive networks
• Overactive networks
• Disrupted communication pathways
• Connectivity patterns associated with symptoms

This information helps determine individualized stimulation targets based on the patient’s own functional network architecture.

Rather than asking, “Where is the target usually located?” the question becomes, “Where is the target located in this particular brain?”

Why anatomical landmarks and functional networks don’t always match

Brain anatomy may look similar between individuals, but functional connectivity can vary significantly.

Research on connectivity-guided neuromodulation has shown that two patients with the same diagnosis may exhibit different network-level patterns that contribute to their symptoms.

This means that a generalized anatomical location may not always correspond to the same functional target from one person to the next.

The goal of fMRI-guided TMS therapy is to reduce that uncertainty by incorporating patient-specific network information into treatment planning.

Comparing the two approaches side by side

Both standard TMS therapy and fMRI-guided TMS therapy use magnetic stimulation. The primary difference lies in how treatment targets are selected.

Targeting method: anatomical estimate vs. functional network data

Standard TMS therapy identifies targets based on generalized positioning techniques.

fMRI-guided TMS therapy uses each patient’s connectivity patterns to identify stimulation targets based on how their brain networks function.

Role of pre-treatment imaging

Most standard protocols do not require functional imaging before treatment.

At Neurotherapeutix, advanced imaging is the first step in the treatment process because it provides the data used for computational brain mapping and individualized treatment planning.

Understanding the differences between rsfMRI and SPECT imaging can help clarify why Neurotherapeutix relies on functional connectivity analysis when developing individualized treatment plans.

How treatment planning differs

Standard approaches focus on applying an established protocol.

fMRI-guided treatment planning begins with understanding the individual’s brain network architecture before determining where stimulation should be delivered.

Monitoring and adjustment during treatment

Both approaches involve ongoing clinical monitoring.

However, fMRI-guided treatment planning provides a more detailed understanding of the underlying network targets being addressed throughout care.

Why precision in targeting matters for outcomes

Brain stimulation is ultimately about influencing neural circuits.

The more accurately those circuits can be identified, the more precisely treatment can be directed.

Individual differences in brain network architecture

No two brains are wired the same way.

While patients may share diagnoses such as depression, anxiety, or OCD, the specific connectivity patterns contributing to symptoms can vary significantly.

This variation is one reason personalized treatment planning has become an area of increasing interest within neuroscience and psychiatry.

What happens when stimulation misses the intended circuit

If stimulation is delivered to a location that does not correspond to the intended functional network, treatment may still influence the brain, but not necessarily the circuit most closely associated with symptoms.

This does not mean standard TMS therapy is ineffective.

It means there may be value in understanding individual network architecture before selecting treatment targets.

How personalized targeting may improve the signal-to-noise ratio

One way to think about individualized targeting is through signal-to-noise ratio.

The goal is to maximize stimulation of the intended network while minimizing unnecessary variability.

By incorporating functional connectivity data into planning, clinicians can deliver stimulation with greater specificity and less reliance on generalized assumptions.

Who may benefit most from fMRI-guided TMS therapy?

Not every patient arrives at treatment for the same reason.

Some individuals are exploring TMS therapy for the first time. Others have already tried medications, psychotherapy, or even standard TMS therapy without achieving their desired results.

Those who haven’t responded to standard TMS therapy

Some patients seek evaluation after completing standard TMS therapy elsewhere.

In these situations, individualized connectivity analysis may provide additional information about treatment targets and network-level contributors to symptoms.

Complex presentations with overlapping conditions

Many patients experience more than one condition at the same time.

For example:

• Depression and anxiety
• PTSD and depression
• OCD and anxiety
• Cognitive symptoms alongside mood concerns

These overlapping presentations may involve multiple interacting networks rather than a single isolated circuit.

People who want a data-informed approach from the start

Some individuals simply prefer a more individualized approach from the beginning.

Rather than relying on generalized positioning methods, they want treatment planning informed by functional imaging and patient-specific connectivity data.

This is particularly common among individuals seeking treatment for depression who want a deeper understanding of how their symptoms may relate to underlying brain network activity before beginning therapy.

The case for knowing where you’re stimulating

The conversation about TMS therapy often centers on whether brain stimulation works.

A more useful question may be: How do you decide where stimulation should be delivered?

Standard TMS therapy and fMRI-guided TMS therapy share the same core technology. The difference is the amount of information used to guide treatment planning.

Our expert team believes understanding your brain’s unique connectivity patterns provides an opportunity to move beyond generalized targeting and toward individualized care.

As the only clinical practice in the United States offering patented fMRI-guided TMS therapy and computational brain mapping, Neurotherapeutix combines functional imaging, connectivity analysis, and individualized targeting to create treatment plans based on how each patient’s brain networks actually function.

If you would like to discuss whether fMRI-guided TMS therapy may be appropriate for your needs, request an appointment with our team.

Frequently asked questions

Is fMRI-guided TMS therapy the same as standard TMS therapy?

No. While both approaches use magnetic stimulation to influence brain activity, the primary difference is how treatment targets are selected.

Standard TMS therapy typically relies on anatomical landmarks to approximate where to stimulate, while fMRI-guided TMS therapy incorporates each patient’s individual functional connectivity data and computational analysis into treatment planning.

Does fMRI guidance mean the treatment takes longer?

The TMS therapy sessions themselves are generally similar. However, fMRI-guided treatment includes additional imaging and computational analysis before treatment begins to support individualized planning.

Is MRI safe? Does it use radiation?

MRI does not use ionizing radiation. According to the National Institute of Biomedical Imaging and Bioengineering, MRI uses magnetic fields and radio waves to generate images and is considered a non-invasive imaging modality when appropriate screening guidelines are followed.

Does Neurotherapeutix accept insurance?

Neurotherapeutix is a private-pay practice. We do not submit claims, communicate with insurance companies, or manage reimbursement requests on behalf of patients. However, we provide visit documentation, clinical records, and billing information for patients who choose to pursue reimbursement independently.

How do I find out if I’m a candidate for fMRI-guided TMS therapy?

The first step is a consultation. During the evaluation process, clinicians review your symptoms, medical history, prior treatments, and treatment goals to determine whether fMRI-guided TMS therapy may be appropriate for your situation.